Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).

Philip Zeuschner; Sebastian Hölters; Michael Stöckle; Barbara Seliger; Anja Mueller; Hagen S Bachmann; Viktor Grünwald; Daniel C Christoph; Arnulf Stenzl; Marc-Oliver Grimm; Fabian Brüning; Peter J Goebell; Marinela Augustin; Frederik Roos; Johanna Harde; Iris Benz-Rüd; Michael Staehler; Kerstin Junker

doi:10.3390/cancers13112594

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).

Philip Zeuschner, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S Bachmann, Viktor Grünwald, Daniel C Christoph, Arnulf Stenzl, Marc-Oliver Grimm, Fabian Brüning, Peter J Goebell, Marinela Augustin (Co-Autor/-in), Frederik Roos, Johanna Harde, Iris Benz-Rüd, Michael Staehler, Kerstin Junker

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Cancers
Jahrgang	13
Ausgabenummer	11
DOIs	https://doi.org/10.3390/cancers13112594
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.3390/cancers13112594

Dieses zitieren

Zeuschner, P., Hölters, S., Stöckle, M., Seliger, B., Mueller, A., Bachmann, H. S., Grünwald, V., Christoph, D. C., Stenzl, A., Grimm, M.-O., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Harde, J., Benz-Rüd, I., Staehler, M., & Junker, K. (2021). Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 13(11). https://doi.org/10.3390/cancers13112594

@article{c33a4582b1fe49b6903213cba18c2e28,

title = "Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).",

keywords = "PROGNOSTIC-FACTORS, CANCER, SUNITINIB, IMMUNOTHERAPY, INHIBITORS, KINETICS, SURVIVAL, TRIAL",

author = "Philip Zeuschner and Sebastian H{\"o}lters and Michael St{\"o}ckle and Barbara Seliger and Anja Mueller and Bachmann, {Hagen S} and Viktor Gr{\"u}nwald and Christoph, {Daniel C} and Arnulf Stenzl and Marc-Oliver Grimm and Fabian Br{\"u}ning and Goebell, {Peter J} and Marinela Augustin and Frederik Roos and Johanna Harde and Iris Benz-R{\"u}d and Michael Staehler and Kerstin Junker",

note = "Augustin, Marinela] Paracelsus Med Univ, Dept Hematol *** Oncol, Nurnberg, Germany",

year = "2021",

doi = "10.3390/cancers13112594",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "11",

}

Zeuschner, P, Hölters, S, Stöckle, M, Seliger, B, Mueller, A, Bachmann, HS, Grünwald, V, Christoph, DC, Stenzl, A, Grimm, M-O, Brüning, F, Goebell, PJ, Augustin, M, Roos, F, Harde, J, Benz-Rüd, I, Staehler, M & Junker, K 2021, 'Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).', Cancers, Jg. 13, Nr. 11. https://doi.org/10.3390/cancers13112594

TY - JOUR

T1 - Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).

AU - Zeuschner, Philip

AU - Hölters, Sebastian

AU - Stöckle, Michael

AU - Seliger, Barbara

AU - Mueller, Anja

AU - Bachmann, Hagen S

AU - Grünwald, Viktor

AU - Christoph, Daniel C

AU - Stenzl, Arnulf

AU - Grimm, Marc-Oliver

AU - Brüning, Fabian

AU - Goebell, Peter J

AU - Augustin, Marinela

AU - Roos, Frederik

AU - Harde, Johanna

AU - Benz-Rüd, Iris

AU - Staehler, Michael

AU - Junker, Kerstin

N1 - Augustin, Marinela] Paracelsus Med Univ, Dept Hematol *** Oncol, Nurnberg, Germany

PY - 2021

Y1 - 2021

KW - PROGNOSTIC-FACTORS

KW - CANCER

KW - SUNITINIB

KW - IMMUNOTHERAPY

KW - INHIBITORS

KW - KINETICS

KW - SURVIVAL

KW - TRIAL

U2 - 10.3390/cancers13112594

DO - 10.3390/cancers13112594

M3 - Original Article (Journal)

C2 - 34070677

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 11

ER -